drugset / Trial / NCT00562289

Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence

NCT00562289 ↗

Phase 3 Completed 664 enrolled Assistance Publique - Hôpitaux de Paris
RandomizedParallel-groupOpen-labelPrevention

Summary

A patent foramen ovale (PFO) is found more frequently in patients with an ischemic stroke than in control subjects. Therapeutic options to prevent stroke recurrence include antiplatelet drugs, oral anticoagulants, and transcatheter closure of the foramen. However, there are no published studies showing convincingly the superiority of any one of these strategies in preventing stroke recurrence. The aim of this randomized clinical trial is to assess whether chronic anticoagulation on the one hand and transcatheter on the other hand are superior to chronic antiplatelet therapy in preventing stroke recurrence.

Timeline

Start
2007-12
Primary completion
2016-12
Completion
2016-12

Outcome

Met primary endpoint

paper hazard ratio, 0.03; 95% confidence interval, 0 to 0.26; P<0.001 PMID 28902593 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule — —
Comparator Aspirin Small molecule — —
Subject Dabigatran Unknown — —
Subject Rivaroxaban Other / unclassified — —